# MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

> **NCT07257185** · PHASE3 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 150 (estimated)

## Conditions studied

- Thyroid Eye Disease (TED)

## Interventions

- **DRUG:** MHB018A injection
- **DRUG:** MHB018A injection Placebo

## Key facts

- **NCT ID:** NCT07257185
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07257185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07257185, "MHB018A Treatment in Patients With Chronic Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07257185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*